Square Pharmaceuticals PLC. (DSE:SQURPHARMA)

Market Cap	187.40B
Revenue (ttm)	75.86B
Net Income (ttm)	23.50B
Shares Out	886.45M
EPS (ttm)	26.51
PE Ratio	7.97
Forward PE	7.81
Dividend	11.00 (5.22%)
Ex-Dividend Date	Nov 24, 2024

Volume	317,421
Average Volume	479,322
Open	n/a
Previous Close	210.60
Day's Range	210.10 - 211.90
52-Week Range	198.90 - 249.80
Beta	0.15
RSI	64.37
Earnings Date	Oct 23, 2025

About DSE:SQURPHARMA

Square Pharmaceuticals PLC., together with its subsidiaries, manufactures, markets, and sells pharmaceutical products in Bangladesh and internationally. The company offers pharmaceutical products comprising alimentary preparations, amoebocides, analgesics, anti-aphthous ulcer, anti-erectile dysfunction, anti-gout, anti-hyperkalemia, anti-osteoarthritis, anti-thyroid, anti-ulcerants, anthelmintics, antiallergies, antianemics, antiasthma, antibiotics, antidiabetics, antifibrinolytics, antihemorrhoidals, antihistamines, antiosteoporotics, antioxid...

• Industry: Pharmaceutical Preparations
• Founded: 1958
• Employees: 12,453
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: SQURPHARMA

Financial Performance

In 2024, DSE:SQURPHARMA's revenue was 70.10 billion, an increase of 15.47% compared to the previous year's 60.71 billion. Earnings were 20.93 billion, an increase of 10.25%.